About site:

Domain name - allozyne.com

Site title - Site title unavailable

Go to website - link to allozyne.com was blocked

Site Logo

IP address:

66.96.130.115

Domain name servers:

ns2.ipower.com ns1.ipower.com

All records:

☆ allozyne.com. 3600 IN A 66.96.130.115
☆ allozyne.com. 3600 IN MX 0 allozyne-com.mail.protection.outlook.com.
☆ allozyne.com. 3600 IN MX 50 ms26848399.msv1.invalid.outlook.com.
☆ allozyne.com. 3600 IN MX 30 mx.allozyne.com.
☆ allozyne.com. 3600 IN NS ns2.ipower.com.
☆ allozyne.com. 3600 IN NS ns1.ipower.com.
☆ allozyne.com. 3600 IN TXT "v=spf1 ip4:66.96.128.0/18 include:websitewelcome.com ?all"
☆ allozyne.com. 3600 IN TXT "v=spf1 include:spf.protection.outlook.com -all"
☆ allozyne.com. 3600 IN SOA ns1.ipower.com. dnsadmin.ipower.com. 2016072413 10800 3600 604800 3600

Domain Name: ALLOZYNE.COM
Registry Domain ID: 213821548_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.register.com
Registrar URL: http://www.register.com
Updated Date: 2022-08-22T08:24:57Z
Creation Date: 2005-09-21T16:43:57Z
Registry Expiry Date: 2024-09-21T16:43:57Z
Registrar: Register.com, Inc.
Registrar IANA ID: 9
Registrar Abuse Contact Email: domain.operations@web.com
Registrar Abuse Contact Phone: +1.8777228662
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.IPOWERDNS.COM
Name Server: NS1.IPOWERWEB.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2024-06-18T03:27:34Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
IP Address Has Reached Rate Limit

Brief facts about allozyne:

Allozyne is a clinical stage biotechnology company headquartered in Seattle's biotech and high tech innovation corridor. Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated by Accelerator Corporation. Its lead product candidate, AZ01, is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic degenerative disease characterized by demyelination of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week. Allozyne's technology also enables the development of next generation antibody-drug conjugates.

AstraZeneca

Pharmaceutical companies of the United States

Companies based in Seattle